A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Study sponsor: X4 Pharmaceuticals
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2027-09Estimated
Enrollment · participants176Estimated
Source updated2026-11-12Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.